Literature DB >> 12878301

Reversible altered consciousness with brain atrophy caused by valproic acid.

Hideo Yamanouchi1, Takako Ota, George Imataka, Eiji Nakagawa, Mitsuoki Eguchi.   

Abstract

A 5-year-old female developed alteration of consciousness during 3 days of long-term treatment with valproic acid for localization-related epilepsy. Computed tomography revealed cerebral atrophy, and electroencephalography presented slow background activity. Consciousness cleared only 12 hours after valproic acid was discontinued, and normal electroencephalography results were evident 1 week later. Cerebral atrophy was nonexistent 2 months later. This rapidly developing but reversible alteration of consciousness in parallel with brain atrophy is recognized as a rare idiosyncratic adverse effect of valproic acid.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12878301     DOI: 10.1016/s0887-8994(03)00005-5

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  2 in total

1.  Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.

Authors:  Pierre N Tariot; Lon S Schneider; Jeffrey Cummings; Ronald G Thomas; Rema Raman; Laura J Jakimovich; Rebekah Loy; Barbara Bartocci; Adam Fleisher; M Saleem Ismail; Anton Porsteinsson; Michael Weiner; Clifford R Jack; Leon Thal; Paul S Aisen
Journal:  Arch Gen Psychiatry       Date:  2011-08

2.  Chronic divalproex sodium use and brain atrophy in Alzheimer disease.

Authors:  A S Fleisher; D Truran; J T Mai; J B S Langbaum; P S Aisen; J L Cummings; C R Jack; M W Weiner; R G Thomas; L S Schneider; P N Tariot
Journal:  Neurology       Date:  2011-09-14       Impact factor: 9.910

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.